NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014.”> Read More
NeuroDerm Announces Pricing of Initial Public Offering
NeuroDerm Ltd. today announced the pricing of its initial public offering of 4,500,000 ordinary shares. NeuroDerm shares are expected to begin trading on the Nasdaq Global Market on November 14, 2014 under the ticker symbol “NDRM.”> Read More
NeuroDerm Announces Launch of Initial Public Offering
NeuroDerm today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC) > Read More